Steady-state clinical pharmacokinetics of bupropion extended-release in youths

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 45, Issue 12, 2006, Pages 1503-1509

  Daviss, W Burleson ^a,b   Perel, James M ^a   Birmaher, Boris ^a   Rudolph, George R ^a   Melhem, Imad ^a   Axelson, David A ^a   Brent, David A ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Adolescence; Bupropion; Developmental pharmacokinetics; Metabolites

Indexed keywords

AMFEBUTAMONE; DRUG METABOLITE; ERYTHROHYDROBUPROPION;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CHILD PSYCHIATRY; CLINICAL ARTICLE; DEPRESSION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; FEMALE; HOSPITALIZATION; HUMAN; MALE; MONOTHERAPY; PATIENT COMPLIANCE; PHARMACODYNAMICS; PHYSICAL EXAMINATION; PRESCRIPTION; PRIORITY JOURNAL; SCHOOL CHILD; STEADY STATE; SUSTAINED RELEASE FORMULATION; TREATMENT DURATION;

ADOLESCENT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BUPROPION; CHILD; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE;

EID: 33845441525     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.chi.0000237704.05143.bd     Document Type: Article

References (21)

1. Barrickman LL, Perry PJ, Allen AJ et al. (1995), Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 34:649-657
2. Bialer M, Yacobi A, Moros D, Levitt B, Houle JM, Munsaka MS (1998), Criteria to assess in vivo performance and bioequivalence of generic controlled-release formulations of carbamazepine. Epilepsia 39:513-519
3. Clein PD, Riddle MA (1995), Pharmacokinetics in children and adolescents. Child Adolesc Psychiatr Clin N Am 4:59-76
4. Conners CK, Casat CD, Gualtieri CT et al. (1996), Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 35:1314-1321
5. Davidson J (1989), Seizures and bupropion: a review. J Clin Psychiatry 50:256-261
6. Daviss WB, Bentivoglio P, Racusin R, Brown KM, Bostic JQ, Wiley L (2001), Bupropion sustained release in adolescents with comorbid attention-deficit/ hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry 40:307-314
7. Daviss WB, Perel JM, Axelson DA (2004), Correlations of plasma levels and ADHD response in juveniles on bupropion SR. Presented at the 44th Annual Meeting of the New Clinical Drug Evaluation Unit (National Institute of Mental Health), Phoenix, June 1-4, 2004
8. Daviss WB, Perel JM, Brent DA et al. (2006), Acute antidepressant response and plasma levels of bupropion and metabolites in a pediatric-aged sample: an exploratory study. Ther Drug Monit 28:190-198
9. Daviss WB, Perel JM, Rudolph GR et al. (2005), Steady-state pharmacokinetics of bupropion SR in juvenile patients. J Am Acad Child Adolesc Psychiatry 44:349-357
10. DeVane CL (2003), Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea. J Clin Psychiatry 64:14-19
11. DeVane CL, Laizure SC, Stewart JT et al. (1990), Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease. J Clin Psychopharmacol 10:328-332
12. Gibaldi M, Perrier D (1982), Noncompartmental analysis based on statistical moment theory. In: Pharmacokinetics, 2nd ed. (Drugs and the Pharmaceutical Sciences). New York: Dekker, pp 409-413
13. Glod CA, Lynch A, Flynn E, Berkowitz C, Baldessarini RJ (2003), Open trial of bupropion SR in adolescent major depression. J Child Adolesc Psychiatr Nurs 16:123-130
14. Hesse LM, Venkatakrishnan K, Court MH et al. (2000), CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176-1183
15. Johnston JA, Fiedler-Kelly J, Glover ED, Sachs DP, Grasela TH, DeVeaugh-Geiss J (2001), Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation.. Nicotine Tob Res 3:131-140
16. Kaufman J, Birmaher B, Brent D et al. (1997), Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980-988
17. Settle EC (1998), Bupropion sustained release: side effect profile. J Clin Psychiatry 4:32-36
18. Steinijans VW (1990), Pharmacokinetic characterization of controlled-release formulations. Eur J Drug Metab Pharmacokinet 15:173-181
19. Tanner JM, Whitehouse RH (1976), Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 51:170-179
20. U.S. Food and Drug Administration (1998), Guidance for industry: General considerations for pediatric pharmacokinetic studies for drugs and biological products. Available at: http://www.fda.gov/cder/guidance/1970dft.pdf. Accessed March 6, 2006
21. Wilens TE, Spencer TJ, Biederman J et al. (2001), A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 158:282-288